Reported about 1 month ago
This article discusses two healthcare stocks, Eli Lilly and Regeneron Pharmaceuticals, that appear ready for a stock split due to their high trading prices. Eli Lilly, with its stock nearing $900, is benefiting from its leading position in the growing weight loss drug market, while Regeneron, whose stock has climbed above $900, may release a split to attract more investors as it faces competition for its key drugs. Both companies are seen as having strong potential for future growth following a split.
Source: YAHOO